These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
441 related items for PubMed ID: 15383485
1. Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Popma JJ, Berger P, Ohman EM, Harrington RA, Grines C, Weitz JI. Chest; 2004 Sep; 126(3 Suppl):576S-599S. PubMed ID: 15383485 [Abstract] [Full Text] [Related]
2. Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Harrington RA, Becker RC, Ezekowitz M, Meade TW, O'Connor CM, Vorchheimer DA, Guyatt GH. Chest; 2004 Sep; 126(3 Suppl):513S-548S. PubMed ID: 15383483 [Abstract] [Full Text] [Related]
3. Antithrombotic therapy in peripheral arterial occlusive disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Clagett GP, Sobel M, Jackson MR, Lip GY, Tangelder M, Verhaeghe R. Chest; 2004 Sep; 126(3 Suppl):609S-626S. PubMed ID: 15383487 [Abstract] [Full Text] [Related]
4. Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Harrington RA, Becker RC, Cannon CP, Gutterman D, Lincoff AM, Popma JJ, Steg G, Guyatt GH, Goodman SG. Chest; 2008 Jun; 133(6 Suppl):670S-707S. PubMed ID: 18574276 [Abstract] [Full Text] [Related]
10. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Kereiakes DJ, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ, REPLACE-2 Investigators. JAMA; 2003 Feb 19; 289(7):853-63. PubMed ID: 12588269 [Abstract] [Full Text] [Related]
11. A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial. Moliterno DJ, TENACITY Steering Committee and Investigators. Catheter Cardiovasc Interv; 2011 Jun 01; 77(7):1001-9. PubMed ID: 21598351 [Abstract] [Full Text] [Related]
14. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Becker RC, Meade TW, Berger PB, Ezekowitz M, O'Connor CM, Vorchheimer DA, Guyatt GH, Mark DB, Harrington RA. Chest; 2008 Jun 01; 133(6 Suppl):776S-814S. PubMed ID: 18574278 [Abstract] [Full Text] [Related]
15. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Chest; 2004 Sep 01; 126(3 Suppl):338S-400S. PubMed ID: 15383478 [Abstract] [Full Text] [Related]